2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. PCSK9

PCSK9

Proprotein convertase subtilisin/kexin type 9

 

PCSK9 Related Products (77):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99187
    Bococizumab
    		Inhibitor 99.80%
    Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia.
    Bococizumab
  • HY-132591
    Inclisiran
    		Inhibitor
    Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research.
    Inclisiran
  • HY-120088A
    PF-06446846 hydrochloride
    		Inhibitor 99.23%
    PF-06446846 hydrochloride is an orally active and highly selective inhibitor of translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9). PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34.
    PF-06446846 hydrochloride
  • HY-132591A
    Inclisiran sodium
    		Inhibitor 98.10%
    Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK9. Inclisiran sodium can be used for hyperlipidemia and cardiovascular disease (CVD) research.
    Inclisiran sodium
  • HY-12402
    SBC-115076
    		Inhibitor 99.54%
    SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism.
    SBC-115076
  • HY-148626
    CVI-LM001
    		Inhibitor
    CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy.
    CVI-LM001
  • HY-161942
    PCSK9-IN-31
    		Inhibitor
    PCSK9-IN-31 (Compound WX002) is an orally active PCSK9 inhibitor. PCSK9-IN-31 can lower low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in high cholesterol fed model rats.
    PCSK9-IN-31
  • HY-163794
    DC371739
    		Inhibitor
    DC371739 is a potent and orally activity PCSK9 inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia.
    DC371739
  • HY-P9928
    Alirocumab
    		Inhibitor
    Alirocumab (REGN 727) is a human monoclonal antibody inhibitor of PCSK9. Alirocumab is a monoclonal antibody. Alirocumab has anti-inflammatory, antiangiogenic and antioxidant effects. Alirocumab can be used in the study of hypercholesterolemia.
    Alirocumab
  • HY-P2276
    Pep2-8
    		Inhibitor 99.74%
    Pep2-8 is a PCSK9 inhibitor with a binding KD of 0.7 μM and an IC50 of 1.4 μM.
    Pep2-8
  • HY-148673
    AZD0780
    		Inhibitor 99.97%
    PCSK9-IN-12 is a heteroaryl compound. PCSK9-IN-12 has bind affinity for PCSK9 with a Kd value of ＜200 nM. PCSK9-IN-12 can be used for the research of cholesterol metabolism.
    AZD0780
  • HY-152221
    PCSK9-IN-10
    		Inhibitor 98.95%
    PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia.
    PCSK9-IN-10
  • HY-12090
    Anacetrapib
    		Inhibitor 99.25%
    Anacetrapib is a potent CETP inhibitor, with IC50s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.
    Anacetrapib
  • HY-143221
    AS-Inclisiran sodium
    		Inhibitor
    AS-Inclisiran sodium is the antisense of Inclisiran. Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research.
    AS-Inclisiran sodium
  • HY-101354
    R-IMPP
    		Inhibitor 98.42%
    R-IMPP (PF-00932239) is an anti-secretagogue of PCSK9 (IC50=4.8 μM), which targets the 80S ribosome to inhibit PCSK9 protein translation.
    R-IMPP
  • HY-P9928A
    Alirocumab (anti-PCSK9)
    		Inhibitor
    Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia.
    Alirocumab (anti-PCSK9)
  • HY-143219
    SS-Inclisiran sodium
    		Inhibitor 98.88%
    SS-Inclisiran (sodium) is a sense strand of Inclisiran. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9.
    SS-Inclisiran sodium
  • HY-150223
    GalNAc unconjugated/naked Inclisiran
    		Inhibitor
    GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA (siRNA) without GalNAc conjugation. GalNAc unconjugated/naked Inclisiran inhibits the transcription of PCSK-9, and can be used for hyperlipidemia and cardiovascular disease (CVD) research.
    GalNAc unconjugated/naked Inclisiran
  • HY-143220
    SS(no Galnac)-Inclisiran sodium
    		Inhibitor
    SS(no Galnac)-Inclisiran (sodium) is a single stran Inclisiran with no GalNAc. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9.
    SS(no Galnac)-Inclisiran sodium
  • HY-152223
    PCSK9-IN-11
    		Inhibitor 99.66%
    PCSK9-IN-11 (compound 5r) is a potent and orally active PCSK9 inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC50 of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be used for atherosclerosis research.
    PCSK9-IN-11